News
Kaerus Bioscience has received US Food and Drug Administration’s (FDA) designations for KER-0193 to treat Fragile X syndrome ...
A new specialist manufacturing facility in Scotland could soon provide solutions to scaling challenges for vital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback